We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and cytopenias who were referred for BMBx between 2002-2018 were identified using the Memorial Sloan Kettering Cancer Center institutional database. Characteristics associated with the risk of t-MN were evaluated by multivariable logistic regression and included in a predictive model. The average area under the receiver operating characteristic curve (AUC) was estimated by 5-fold cross-validation. Of the 206 BC patients who underwent BMBx included in our study, 107 had t-MN. By multivariable analysis, white blood cell count 4-11 K/mcL, absolute neutrophil count (ANC) /1.5 K/mcL, hemoglobin h12.2 g/dL, red cell distribution width 11.5-14.5%, the presence of bone metastasis and a time from BC diagnosis to BMBx.

中文翻译：

---

常规临床参数和实验室检测可预测乳腺癌治疗后与治疗相关的髓系肿瘤。

我们的目标是确定乳腺癌 (BC) 和血细胞减少患者治疗相关髓系肿瘤 (t-MN) 的预测因子，以确定骨髓活检 (BMBx) 的时机。使用 Memorial Sloan Kettering 癌症中心机构数据库确定了 2002-2018 年间转诊接受 BMBx 的 BC 和血细胞减少患者。通过多变量逻辑回归评估与 t-MN 风险相关的特征，并将其纳入预测模型。接受者操作特征曲线 (AUC) 下的平均面积通过 5 倍交叉验证进行估算。在我们研究中包括的 206 名接受 BMBx 的 BC 患者中，107 名患有 t-MN。通过多变量分析，白细胞计数 4-11 K/mcL，绝对中性粒细胞计数 (ANC) /1.5 K/mcL，血红蛋白 h12.2 g/dL，红细胞分布宽度 11.5-14.5%，